Although only 2% of SKMs were reported to be associated with KRAS mutations, because of their possible weaker oncogenic activity in melanocytes than the other isoforms [36], several other papers highlighted the presence of KRAS mutations in melanoma cell lines [36,37]. This evidence concerns the gene KRAS and melanoma.